Objectives: To determine whether nondesmoglein (nonDsg) autoantibodies are pathogenic and whether they recognize keratinocyte cholinergic receptors that control cell adhesion because antikeratinocyte autoimmunity in patients with pemphigus vulgaris is not limited to the development of autoantibodies to Dsg.
S
KIN BLISTERS occur in a variety of dermatologic conditions. Blisters in pemphigus are associated with the binding of IgG autoantibodies to keratinocyte cell-surface molecules.
1 These "intercellular" or "pemphigus" antibodies bind to keratinocyte desmosomes and to desmosome-free areas of the keratinocyte cell membrane. 2, 3 Intercellular spaces enlarge, desmosomes decrease in number and eventually disappear, and the cells round up and detach from one another without cell death. [4] [5] [6] [7] This phenomenon is called "acantholysis." Use of high doses of glucocorticosteroids (prednisone, sometimes up to 1000 mg/d 8 ) is required to suppress acantholysis. Corticosteroids are the mainstream of pemphigus management, but use of these drugs can cause severe adverse effects and complications, including death. 9, 10 The development of nonhormonal treatment of patients with pemphigus is pending elucidation of the pathophysiological pathways mediating acantholysis.
Some IgG antibodies found in serum from patients with pemphigus bind
PASSIVE TRANSFER OF PEMPHIGUS ANTIBODIES TO NEONATAL MICE LACKING Dsg 3
The IgG fractions that did not cross-react with Dsg 1 were isolated from pemphigus vulgaris and normal-control serum samples by precipitation with 33% ammonium sulfate followed by dialysis in phosphate-buffered saline solution, pooled and injected intraperitoneally through a 30-gauge needle at a dose of 20 mg per 1 g of body weight into 10-to 12-hour-old progeny from 5 different litters that resulted from breeding 3 heterozygous female mice and a homozygous male (129 ϫ BL/6)-Dsg3 null mouse.
GENOTYPING
Among neonates with antibody-induced pemphigus, the homozygous Dsg3 null mice lacking Dsg 3 were identified using polymerase chain reaction amplification of the sequences of genomic DNA extracted from tails of mice using a tissue kit (QIAamp, Qiagen, Santa Clarita, Calif). The polymerase chain reaction used 2 different sets of primers to amplify 2 different products from the wildtype Dsg3 gene. The first pair of Dsg 3 primers included the sense primer 5Ј-GGAGGAACAGACTAACAGGC-3Ј matching the sequence located upstream of the ATG starting codon of the Dsg3 gene, and the antisense primer 5Ј-ACCATCAGGAGGGCCAGAGA-3Ј, matching within the 3Ј end portion of the first exon (expected product size is 200 base pairs [bp] ). The second pair of Dsg 3 primers included the sense primer 5Ј-TCTCTGGCCCTCCTGATGGT-3Ј , matching the position of the antisense primer of the first pair of primers, and the antisense primer 5Ј-CTCCCAACTCGTCTAGAGTC-3Ј, matching within the 5Ј end portion of the first intron of the mouse Dsg3 gene 40 (expected product size is 500 bp). Another pair of primers, 5Ј-AGGTGAGATGACAGGAGATC-3Ј and 5Ј-CTTGGGTGGAGAGGCTATTC-3Ј (expected product size is 280 bp), matched within the sequence of the neomycin resistance gene of the plasmid pPNT used to engineer the Dsg3 null mice. 13 The polymerase chain reactions were carried out as described previously, 41 including preheating at 94°C for 4 minutes; hot start with tag DNA polymerase (Promega, Madison, Wis); then 35 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 3 minutes.
ISOLATION OF KERATINOCYTE CHOLINERGIC RECEPTORS
Keratinocyte cholinergic receptors were prepared from fresh human neonatal foreskins by incubating 5 ϫ 5-mm pieces of minced foreskin for 90 minutes at 37°C and 5% carbon dioxide in RPMI 1640 medium (Sigma Chemical Co) supplemented with EDTA, 20 mmol. The epidermis was then scraped with a blade from underlying dermis, placed in ice-cold buffer A consisting of sodium phosphate buffer, 50 mmol (pH 7.4), supplemented with the following protease inhibitors: phenylmethylsulphonyl fluoride, 0.5 mmol; iodoacetamide, 1 mmol; benzamidine, 1 mmol; bacitracin, 0.1 mg/mL; leupeptin, 4 µg/ mL; soybean trypsin inhibitor, 5 µg/mL; pepstatin A, 1 µg/mL; EDTA, 1 mmol; phenathroline, 0.5 mmol; and aprotinin, 1 to keratinocyte desmosomal cadherins, desmoglein (Dsg) 1 and Dsg 3.
11 These cadherinlike molecules hold keratinocytes together. Because keratinocytes in pemphigus undergo acantholysis, a direct causal relationship of antiDsg antibody and pemphigus acantholysis seemed certain. However, neither transgenic mice with truncated Dsg 3 12 nor Dsg 3-knockout (ie, Dsg3 null ) mice 13 spontaneously develop visible skin blisters, implicating the involvement of novel keratinocyte cell-surface molecules and linked pathophysiological pathways. Indeed, IgGs from pemphigus serum samples recognize other keratinocyte proteins with molecular mass or molecular structure different from Dsg 1 and Dsg 3.
14-22 The pathophysiological significance of these non-Dsg antibodies remained unidentified.
Acetylcholine regulates adhesion and motility of human epidermal keratinocytes, and activation of cholinergic receptors can prevent, stop, and reverse acantholysis elicited by pemphigus antibodies in vitro. 23 In the epidermis, acetylcholine acts as a cytotransmitter subserving a biologically active, cytokinelike cholinergic network. 24 Human keratinocytes synthesize, store, release, and degrade acetylcholine. 25 In epidermis, the autocrine-and paracrine-acting acetylcholine alters cellular functions by acting on keratinocyte cholinergic receptors of muscarinic and nicotinic classes. 26, 27 Cholinergic receptors expressed by keratinocytes accumulate within regions of the cell membrane associated with the sites of cell-cell attachment (ie, at desmosomes), 26 precisely where pemphigus IgG accumulates, as visualized by immunoelectron microscopy. 28 The location of these receptors suggests their involvement in regulating cell-cell attachments mediated by cadherin molecules. 29 Inactivating keratinocyte cholinergic receptors using muscarinic (atropine sulfate) or nicotinic (mecamylamine hydrochloride) antagonists leads to reversible cell-cell detachment and acantholysis in keratinocyte monolayers. 23, 27 Patients with pemphigus occasionally develop myasthenia gravis. This autoimmune disease of neuromuscular transmission is caused by antibodies to cholinergic receptors expressed by muscle cells. 30 Coexistent pemphigus and myasthenia gravis often develop in patients with thymoma, and the autoantibodies are directed toward epithelial, muscle, and thymic antigens. 31 Autoantibodies causing neuromuscular block in patients with myasthenia gravis recognize cholinergic receptors expressed on the cell surface of thymic epithelial cells. [32] [33] [34] These cells can be stained specifically with pemphigus IgGs. 35 Therefore, cholinergic receptor(s) expressed by epidermal keratinocytes might share common antigenic epitope(s) with muscle and thymic cholinergic receptors. Results of pilot studies by Grando et al 36 demonstrate that pretreatment of normal human epidermis with serum from a patient with coexistent pemphigus, myasthenia, and benign lymphocytic thymoma prevents staining of keratinocytes with rabbit antibody, recognizing a unique sequence region present in the µg/mL (all from Sigma Chemical Co), and homogenized with a tissue-and-cell disrupter (Omni 2000, PGC Scientific, Gaithersburg, Md). Cell nuclei were removed by centrifugation at 1000g for 10 minutes at 4°C, and plasma membranes were separated from the resultant supernatants by centrifugation at 40 000g for 60 minutes at 4°C. To solubilize cholinergic receptors from the plasma membranes, the samples were incubated in buffer A supplemented with 1% wt/vol digitonin and 0.1% wt/vol sodium cholate (both from Sigma Chemical Co) for 30 minutes followed by a 30-minute centrifugation at 100 000g at 4°C. 26 Protein concentration was determined using the Micro BCA kit (Pierce, Rockford, Ill), and the presence of cholinergic receptors was demonstrated by saturable specific binding (B max = 0.9 nmol/0.175 mg protein) with the cholinergic radioligand [ carboxyterminal of the ␣3 subunit of the keratinocyte cholinergic receptor. The IgGs from this patient also precipitated a radiolabeled cholinergic receptor solubilized from keratinocyte membranes.
Results of the present study demonstrate that (1) non-Dsg 1 and non-Dsg 3 serum antibodies from patients with pemphigus vulgaris are pathogenic because they induce suprabasilar acantholysis and extensive skin blistering in neonatal mice and (2) some of these nonDsg 1 and non-Dsg 3 antibodies can be directed against keratinocyte cholinergic receptors because, as measured in the radioimmunoprecipitation assay (RIPA), pemphigus vulgaris and pemphigus foliaceus IgGs precipitate cholinergic receptors solubilized from human keratinocytes and covalently labeled with the cholinergic radioligand [ 3 H]propylbenzilylcholine mustard ([ 3 H]PrBCM). These results suggest that acantholysis in patients with pemphigus is mediated through an autoantibody-induced inactivation of keratinocyte cholinergic receptor(s), disrupting the physiologic control of cell adhesion.
RESULTS

BINDING OF PEMPHIGUS ANTIBODIES TO KERATINOCYTES IN THE EPIDERMIS OF MICE LACKING Dsg 3
To test the hypothesis that antikeratinocyte autoimmunity in pemphigus vulgaris is not limited to antibodies against Dsg 3, we performed IIF experiments testing the ability of patients' serum to bind to keratinocytes in the epidermis of (129 ϫ BL/6)-Dsg3 null mice, which lack Dsg 3. All pemphigus vulgaris serum samples stained both interfollicular (Figure 1 , A) and follicular ( Figure 1 , B) areas of epidermis in a fishnetlike, pemphigus pattern consistent with binding of non-Dsg 3 pemphigus antibodies to keratinocyte membranes. When the intensities of fluorescence of Dsg 3-free (ie, Dsg3 null ) and Dsg 3-containing (ie, Dsg3 + / +) specimens were compared by a semiquantitative IIF assay, the epidermis of Dsg3 null mice immunoreacted with approximately 58% of the relative amounts of pemphigus IgGs bound in the epidermis of the Dsg3 + / + BALB/c mice, defined as 100%.
Because some patients with generalized pemphigus vulgaris may develop antibodies to Dsg 1, 43 we examined the immunospecificities of the pemphigus vulgaris serum samples that stained the epidermis of Dsg3 null mice. It was found that the immunoreactivity of these serum samples was limited to epidermal proteins with apparent molecular masses of 40, 60, and 70 kd, in addition to the 130-kd Dsg 3 band, and specifically excluded the Dsg 1 band of 160 kd ( Figure 2 , lanes 1-3). Epidermal extract used for immunoblotting included the intact Dsg 1 antigen because it was visualized by antibodies from pemphigus foliaceus serum (Figure 2, lane 4) .
These pemphigus vulgaris serum also specifically stained keratinocyte membranes in the epidermis of another genetic stock of Dsg 3-negative mice, namely, "balding" C57/6-Dsg3
bal mutant mice (data not shown). These mice have a spontaneous recessive mutation within the Dsg3 locus on mouse chromosome 18 44 and do not express Dsg 3. 13 The absence of Dsg 3 from Dsg3 null and Dsg3 bal / Dsg3 bal epidermal specimens was confirmed by their negative staining with an antibody to Dsg 3 protein that stained keratinocytes in the epidermis of control BALB/c, C57Bl/ 6 + /-, and (129 ϫ BL/6) + /Dsg3 null mice equally efficiently (data not shown).
PATHOGENICITY OF NON-Dsg 1 AND NON-Dsg 3 ANTIBODIES FROM PEMPHIGUS VULGARIS SERUM
The observation that serum autoantibodies from patients with pemphigus vulgaris stain epidermis of mice lacking Dsg 3 in the pemphigus-specific pattern led us to determine whether these non-Dsg 1 and non-Dsg 3 antibodies are pathogenic. Because neonatal Dsg3 null mice do not show any evidence of spontaneous acantholysis and blistering, 13 these pups were chosen as the animal model to further study the pathophysiological significance of non-Dsg 1 and non-Dsg 3 antibodies produced by patients with pemphigus vulgaris.
The intraperitoneal injection of pooled pemphigus vulgaris IgG fractions that did not cross-react with Dsg 1 (Figure 2, lanes 1-3) , but not normal human IgGs, into 1-day-old progeny of Dsg3 null mice or control Dsg3 + / + A B Figure 1 . Binding of pemphigus vulgaris antibodies to keratinocytes in the epidermis of mice lacking desmoglein (Dsg) 3. Indirect immunofluorescence staining of the abdominal skin of a Dsg3 null mouse in which the lack of Dsg 3 expression was confirmed by the absence of staining with an antibody to Dsg 3 protein (data not shown). The fishnetlike intercellular staining is seen in both interfollicular (A) and follicular (B) epidermal areas (original magnification ϫ1000).
BALB/c mice produced gross skin blistering approximately 18 to 24 hours after injection in both groups. There were no differences in the time of onset or in the extent of blister formation between these 2 breeds that differed in Dsg 3 expression. At the onset of skin blistering, the following 3 variants of the Nikolsky sign, 45 representing a loss of intraepidermal cohesion, were elicited: (1) peripheral enlargement of an intact blister secondary to vertical pressure on its roof, (2) linear extension of the margin of the existing erosion by pulling the remnant of blister roof with tweezers, and (3) epidermal split of clinically noninvolved skin by applying lateral traction with a pencil eraser. When blisters became generalized, the mice were killed, and the homozygous Dsg3 null pups were identified by genotyping. Visualization of 2 polymerase chain reaction products of 200 and 500 bp identified the homozygous Dsg3 + / + mouse, 3 products of 200, 500, and 280 bp indicated the heterozygote Dsg3 + /-mouse, and 1 product of 280 bp represented the homozygous Dsg3-/-, or Dsg3 null , mouse (Figure 3) . The gross and microscopic changes of the skin of a Dsg3 null mouse injected with pemphigus IgGs are shown in Figure 4 . All littermates were normal at birth (injection of healthy IgGs did not induce any gross or microscopic changes of the skin of Dsg3 null mice or their littermates; Figure 4 , A). By 18 hours after injection, a flaccid skin blister with serous exudate spontaneously developed on the abdomen of a Dsg3 null mouse (Figure 4, B) . At this time, the Nikolsky sign was elicited (Figure 4, C) .
Light microscopic examination of the marginal blistered areas revealed intraepidermal pathologic changes with suprabasilar acantholysis and basilar "tombstoning" characteristic of pemphigus vulgaris (Figure 4, D) . Early stages of keratinocyte cell-cell detachment were observed in biopsy specimens of clinically noninvolved skin (Figure 4, E) . This likely accounts for the positive Nikolsky sign on intact skin. Direct immunofluorescence of both lesional and clinically normal skin showed pemphigus IgG localized to keratinocyte cell membranes, producing the classic fishnetlike, pemphigus staining pattern (Figure 4, F) .
REACTION OF PEMPHIGUS ANTIBODIES WITH KERATINOCYTE CHOLINERGIC RECEPTORS
Pemphigus serum samples were found to specifically react with keratinocyte cholinergic receptors. The mean absolute values of radioactivity precipitated by pemphigus serum samples always significantly (PϽ.05) exceeded both the disease-control and the normal-control values ( Figure 5) . Radioactivity precipitated by diseasecontrol serum samples in RIPA did not significantly differ from that precipitated by normal human serum samples ( Figure 5) .
Analysis of standardized results comparing individual pemphigus serum samples (Figure 6 ) revealed that 34 (85%) of 40 pemphigus serum samples precipitated more radioactivity than their reference control values. The mean radioactivity precipitated by these 34 pemphigus serum samples exceeded their reference control values by a mean of 2.6 times (range, 1.1-7.8).
The clinical form of pemphigus did not affect the ability of serum to precipitate cholinergic receptors. Pemphigus vulgaris and pemphigus foliaceus serum precipitated the receptors equally efficiently (Figure 6 ).
COMMENT
The pathophysiology of pemphigus vulgaris is not limited to the autoimmunity against the keratinocyte adhe- We studied non-Dsg antibodies in pemphigus because of the failure to identify Dsg 3 as an exclusive target molecule responsible for the clinical manifestations of pemphigus. The following observations suggest that keratinocyte cell-surface molecules other than Dsg 3 are responsible for blister formation in patients with pemphigus vulgaris: 3 46 ) are present at significant titer in the serum of approximately half of the first-degree relatives of patients with pemphigus vulgaris but fail to cause any skin or mucous membrane changes. 47 2. Neonatal mice injected with pemphigus vulgaris IgG purified by a fusion protein representing the "pathogenic" extracellular domains of Dsg 3, ie, EC1 and EC2, show pemphiguslike epidermal staining and signs of cell-cell detachments visible on microscopy but do not develop gross skin blistering despite an appreciable titer of antibody in mouse serum. 48 3. Transgenic mice with amino terminal deletion of Dsg 3 show swelling of paws and digits, focal flakiness of the skin, and necrotic changes on the tips of the tails but no loss of cell-cell adhesion and no evidence of skin blisters. 12 
Intercellular autoantibodies recognizing the 130-kd epidermal protein (Dsg
The homozygous balding Dsg3 bal /Dsg3
bal mice harboring a spontaneous recessive mutation that inactivates Dsg3 gene expression show alopecia and mucous membrane vesicles and erosions but only rare interfollicular epidermal changes and no visible blisters. 13, 49 (5) Dsg3 null mice with a targeted null mutation of the Dsg3 gene are healthy at birth but develop runting and hair loss around the time of weaning and may exhibit crusted lesions around the eyes, on the snout, and on the nipples of nursing mothers, apparently from trauma. These mice, however, do not develop spontaneous skin blisters or extensive erosions. 13 In addition to the 130-kd Dsg 3 and 85-kd plakoglobin complex, 50 patients with pemphigus may develop antibodies to keratinocyte proteins with apparent molecular masses of 12, 18, 47, 50, 52, 55, 59, 66, 67, 68, 75, 78, 102, 105, 180, and 190 kd. [14] [15] [16] [17] [18] [19] [20] [21] [22] Rabbit antibody raised against the 66-kd protein reproduced pemphigus in 4 of 5 injected mice. 19 The pemphigus vulgaris serum samples used in the present study to induce pemphigus in neonatal Dsg3 null mice also recognized keratinocyte proteins with apparent molecular masses of 40, 60, and 70 kd. Binding of pemphigus IgGs to one of these yet unidentified keratinocyte antigens may mediate acantholysis and blistering. To rule out a possibility that conformational epitope of Dsg 1 was destroyed in the course of immunoblotting procedures, thus rendering false-negative results, the immunoreactivities of pemphigus vulgaris IgGs that can induce symptoms of pemphigus in neonatal Dsg3 null mice were further characterized by a combination of immunoprecipitation techniques featuring various degrees of sensitivity and specificity (V.T.N. and S.A.G., unpublished data, 1998). The absence of immunoreactivity of these serum samples with the 160-kd Dsg 1 antigen precludes the possibility that the serum targeted this desmosomal cadherin to cause acantholysis.
The fate of pemphigus antibodies subsequent to binding to the cell surface of cultured murine keratinocytes suggests that pemphigus antibody interacts with its target in a receptor/ligand manner, 7 eliciting an intracellular signal that translates into abnormalities in adhesive function of the cells. Accordingly, binding of pemphigus IgGs to cultured keratinocytes causes activation of phospholipase C, production of inositol 1,4,5-trisphosphate, Ca 2+ influx and rapid transient increase of intracellular Ca 2+ , changes in the intracellular cyclic adenosine monophosphate-cyclic guanosine monophosphate ratios, and activation and translocation of protein kinase C from the cytosol to the particulate and/or cytoskeleton fractions. 21, [51] [52] [53] [54] The expression and/or function of the proteins mediating intercellular junctions of keratinocytes is also regulated by the protein kinase Cmediated pathway, 55, 56 and binding of pemphigus antibodies to cultured keratinocytes leads to phosphorylation of desmosomal cadherins. 57 Therefore, it is reasonable to speculate that binding of pemphigus antibody to keratinocyte cell-surface receptor(s) initiates an intracellular signaling cascade that leads to disassembly of desmosomes. Reference control values (RCVs) for each tested pemphigus serum sample. In these experiments, each radioimmunoprecipitation assay (RIPA) tested several pemphigus serum samples along with 1 sample of disease-control serum, which provided the RCV for test pemphigus serum. The test pemphigus serum samples and the reference serum sample were drawn at approximately the same time and stored frozen under the same conditions. All samples were tested in triplicate or quadruplicate. The radioactivity precipitated by a test pemphigus serum sample was divided by the mean value of radioactivity precipitated by the reference serum sample run in the same RIPA to compute the RCV for a given pemphigus serum sample. Shown in this graph are means ± SDs of the amounts of Propylbenzilylcholine, like atropine, specifically binds to the muscarinic class of cholinergic receptors, 66 and a muscarinic receptor has been implicated in mediating control of cell adhesion by the cholinergic drug carbachol via a protein kinase C-mediated pathway that activates Ecadherin. 29 We therefore speculate that pemphigus antibodies target one of several molecular subtypes of muscarinic cholinergic receptors expressed on the surface of human keratinocytes. 67 However, it also has been shown that PrBCM can label nonmuscarinic receptors, such as amiloride-sensitive Na + /H + -exchanger. 68 Pemphigus IgGs may precipitate other keratinocyte cholinergic molecules binding [ 69 We propose that acantholysis in pemphigus is mediated by at least 2 complementary pathogenic pathways, namely, (1) anticholinergic receptor antibody that weakens intercellular adhesions between keratinocytes via inactivation of the cholinergic receptor-mediated physiologic control of cadherin (Dsg) expression and/or function and causes dyshesion, cell detachment and rounding up, or acantholysis and (2) antibodies to adhesion molecules that prevent formation of new desmosomes in acantholytic keratinocytes by blocking the extracellular domains of desmosomal cadherins that mediate homophilic adhesion.
These separate pathophysiological pathways targeting 2 different types of keratinocyte cell-surface molecules (ie, cholinergic receptor and Dsg) may explain the low-and high-affinity binding of pemphigus IgGs to keratinocytes. 70 The present results indicate that anti-Dsg 3 antibodies represent approximately 40% and that nonDsg 3 antibodies represent approximately 60% of the total antikeratinocyte autoantibodies circulating in the serum of patients with pemphigus vulgaris who do not develop antiDsg 1 antibodies. The existence of at least 2 types of antikeratinocyte antibodies in pemphigus may reconcile the failure of recombinant proteins representing different portions of Dsg 3 to pre-absorb from pemphigus serum the antibodies that can induce pemphigus in neonatal mice. 48 Complete absorption of disease-causing antibodies has been achieved using a chimeric protein representing a combination of Dsg 3 with the constant region of human IgG1. 71 The combination of Dsg 3 and IgG1 peptide region may create a conformational epitope that mimics pathogenic pemphigus vulgaris antigen. Because pemphigus vulgaris IgGs that do not cross-react with Dsg 1 reproduce pemphigus in Dsg3 null mice lacking Dsg 3, anti-Dsg 3 antibody and Dsg 3 itself unlikely play critical roles in the pathophysiological development of pemphigus. Perhaps the folding of the chimeric protein simulates some other keratinocyte protein, such as cholinergic receptor. Alternatively, the disease-causing antibodies may have been eliminated through their affinity to the IgG1 portion of the chimeric protein. It recently has been proposed that selected autoantibodies produced during the course of an autoimmune disease behave as adhesion molecules via molecular mimicry of the motif involved in protein-protein adhesion. 72 In conclusion, the results of this study provide the first direct evidence that the antibodies to the keratinocyte cell surface molecules other than Dsg 1 and Dsg 3, which are produced by patients with pemphigus vulgaris, are indeed pathogenic. These novel, pathophysiologically important targets may include keratinocyte cholinergic receptor(s). The presence of antibodies against keratinocyte cholinergic receptors in pemphigus, together with the knowledge that cholinomimetic drugs can modulate pemphigus IgG-induced acantholysis in vitro, 23 suggests that clinical trials of tissue-or receptor-class-specific cholinomimetics may be warranted in both pemphigus vulgaris and pemphigus foliaceus. Studies are in progress to identify the molecular structure of keratinocyte cholinergic receptor (s) precipitated by pemphigus serum and to determine other novel antigens recognized by pemphigus antibodies.
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